Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including ...

Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and ongoing portfolio ...

Bruker Corporation BRKR recently launched the new X4 POSEIDON, a high-performance 3D X-ray microscope (XRM) using ...

Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 ...

M&T Bank Corp lifted its stake in Bruker Co. (NASDAQ:BRKR – Free Report) by 303.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 17,870 shares of the medical ...

Stock analysts at Zacks Research upped their Q4 2025 EPS estimates for Bruker in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst R. Department now ...

Good day, and welcome to the Bruker Corporation Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the ...

Bruker exceeded both EPS and revenue forecasts for Q4 2024. The company reported a 14.6% year-over-year increase in quarterly revenue. Stock price decreased by 0.77% despite the earnings beat.

Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative ...

Bruker Corporation BRKR recently launched the new X4 POSEIDON, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). Representing a significant leap in benchtop ...

Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.